PFIZER INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- Drug: AN2728 Topical Ointment, 2%Drug: Matching vehicle control
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 763
- Registration Number
- NCT02118766
- Locations
- ๐บ๐ธ
Anacor Investigational Site, Stockbridge, Georgia, United States
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
- Conditions
- Clostridium Difficile Associated Disease
- Interventions
- Biological: PlaceboBiological: Clostridium difficile vaccine
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 185
- Registration Number
- NCT02117570
- Locations
- ๐บ๐ธ
Meridian Clinical Research, Norfolk, Nebraska, United States
๐บ๐ธClinical Research Atlanta, Stockbridge, Georgia, United States
๐บ๐ธAvail Clinical Research, LLC, DeLand, Florida, United States
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2017-12-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT02114203
- Locations
- ๐บ๐ธ
University of Illinois at Chicago Clinical Research Center, Chicago, Illinois, United States
๐บ๐ธBoston Medical Center, Boston, Massachusetts, United States
๐บ๐ธUniversity of Illinois Hospital and Health Sciences System, Chicago, Illinois, United States
A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body
- Conditions
- Healthy
- Interventions
- Drug: [14C] PF-04449913
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT02110342
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Madison, Wisconsin, United States
Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies
- Conditions
- Metastatic Cancer Pancreas
- Interventions
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3
- Registration Number
- NCT02109445
- Locations
- ๐บ๐ธ
Anschutz Inpatient Pavilion, Aurora, Colorado, United States
๐บ๐ธUniversity of Colorado Denver, CTO (CTRC), Aurora, Colorado, United States
๐บ๐ธUniversity of Rochester Investigational Drug Pharmacy, Rochester, New York, United States
Post Marketing Surveillance Study For Sayanaยฎ
- Conditions
- Product Surveillance, Postmarketing
- Interventions
- Other: Non intervention
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 362
- Registration Number
- NCT02104557
- Locations
- ๐ฐ๐ท
Inje University Haeundae Paik Hospital, Haeundae-gu, Busan, Korea, Republic of
๐ฐ๐ทBundang Cha Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
๐ฐ๐ทAjou University Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of
Drug Interaction Study Between Bosutinib And Dabigatran
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT02102633
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, DeLand, Florida, United States
Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain
- Conditions
- Moderate-severe Pain
- Interventions
- Drug: Ages 7-11Drug: ages 12-17
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2020-07-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 19
- Registration Number
- NCT02101554
- Locations
- ๐บ๐ธ
UCI Medical Center- Outpatient Pharmacy, Orange, California, United States
๐บ๐ธUniversity of California, Irvine Health-Inpatient Pharmacy, Orange, California, United States
๐บ๐ธGottschalk Medical Plaza, Irvine, California, United States
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
- Conditions
- Hyperlipidemia
- Interventions
- Other: Placebo
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 746
- Registration Number
- NCT02100514
- Locations
- ๐จ๐ฆ
Manna Research Inc., Toronto, Ontario, Canada
๐บ๐ธlntermed Group, Los Angeles, California, United States
๐บ๐ธAmerican Institute of Research, Los Angeles, California, United States
Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2014-05-13
- Lead Sponsor
- Pfizer
- Registration Number
- NCT02100527